EU filing for GSK’s shingles jab
GlaxoSmithKline has submitted its experimental shingles vaccines to European regulators, seeking approval to market its use to prevent herpes zoster (shingles) in people aged 50 years or over.
Read More
Tag: herpes zoster
First filing for GSK’s shingles vaccine
GlaxoSmithKline has filed Biologics License Application in the US for Shingrix, seeking approval to market the vaccine for the prevention of herpes zoster (shingles) in people aged 50 years or over.
Read More
Sanofi Pasteur MSD’s shingles jab OK’d for UK’s immunisation scheme
Sanofi Pasteur MSD’s shingles (herpes zoster) vaccine has been cleared for continued use in the UK’s national immunisation programme for at least the next two years, following an evaluation of the vaccine’s clinical and cost effectiveness.
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
